Tissue Diagnostics Market

Tissue Diagnostics Market by Product (Consumables (Antibodies, Reagents, Tissue, Probes), Instrument (Processing System, Scanner)), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) & Region - Global Forecast to 2028

Report Code: MD 2349 Jan, 2024, by marketsandmarkets.com

The global tissue diagnostics market in terms of revenue was estimated to be worth $5.6 billion in 2023 and is poised to reach $8.4 billion by 2028, growing at a CAGR of 8.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is driven by the growing private diagnostic centers globally, and rising geriatric population with subsequent growth in chronic and infectious diseases. On the other hand, high degree of consolidation and high cost of diagnostic imaging system are expected to restrain the growth of this market to a certain extent.

Attractive Opportunities in the Tissue Diagnostics Market

Tissue  Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Tissue  Diagnostics Market

Tissue Diagnostics Market Dynamics

DRIVER: Growing demand for digital pathology

Digital pathology systems are increasingly being utilized by healthcare professionals across the globe due to the ongoing trend of automation of diagnostic laboratory processes across major healthcare markets. Moreover, improved laboratory efficiency is critical for healthcare providers and patients for accurate and timely disease diagnosis to devise effective disease management strategies. With the greater utilization of digital and automated processes, laboratory technicians can offer accurate and affordable disease diagnoses in a time-bound manner. As a result, major healthcare service providers are adopting digital pathology systems and related software to offer efficient and affordable services to their customers.

Globally, governments and industry entities are directing their attention toward diverse strategies within the realm of digital pathology, aiming to offer highly advanced, swift, and precise diagnostic solutions. Highlighted are key advancements which mentioned in below:

  • In January 2023, Agilent Technologies, Inc. has entered into a partnership with Akoya Biosciences, Inc. to develop multiplex-immunohistochemistry diagnostic solutions. This collaboration intends to commercialize workflow solutions for multiplex assays dedicated to tissue analysis, ultimately providing a comprehensive multiplex IHC solution for biomarker clinical research, facilitated by digital pathology.
  • In June 2022, Roche introduced the VENTANA DP 600 slide scanner, a digital pathology system designed for generating digital representations of stained tissue samples.

These advancements, coupled with the emergence of high-tech and diagnostic firms, are anticipated to drive market growth.

RESTRAINT: Stringent Regulatory requirement

The FDA's current approval process for tissue diagnostic tools and consumables poses a significant hurdle for companies aiming to introduce innovative products. Many of these fall under Class III, requiring exhaustive Premarket Approval (PMA) that scrutinizes safety and effectiveness, marking the most rigorous application route.

The recent release of FDA guidance documents further adds to the complexity. Any alterations to devices demand a 510(k) submission, whether for software updates, installations, or other modifications. Meanwhile, in the EU, In Vitro Diagnostic (IVD) products adhere to a distinct regulation, with the forthcoming Medical Device Regulation (MDR) and In Vitro Diagnostic Device Regulation (IVDR) adding more stringent criteria for CE Marking, crucial for market legality.

Aligning with these stringent regulations presents a challenge for market players. Adapting processes to comply with these norms may affect the launch timelines for new products, especially in the US and Europe, potentially creating temporary market entry delays.

OPPORTUNITY: Significant opportunities in BRICS Countries

Growing markets like India, China, and Brazil are poised to become pivotal growth arenas for industry stakeholders in the foreseeable future. As per SRB's analysis, the BRICS nations are projected to collectively contribute 50% to the global GDP by 2030, with a combined annual GDP of USD 24,142,139 million in 2021. Notably, each of these nations has seen consistent annual GDP increases; for instance, China's GDP has surged nearly sixfold since 2003. This economic upswing is anticipated to fuel expansion in the healthcare sector, presenting lucrative prospects for participants in the market.

Furthermore, the sizable population base, especially in India and China, forms a sustainable diagnostic market. Lifestyle shifts and suboptimal diets in these regions have elevated the prevalence of chronic ailments such as cancer, cardiovascular diseases (CVDs), and autoimmune disorders. The rising incidence of chronic conditions, coupled with a substantial patient pool in these regions and augmented healthcare spending, is set to create substantial growth avenues for market players. For instance, the NIH estimates India had 1,461,427 cancer patients in 2022. Similarly, China accounted for 24% of newly diagnosed cases and 30% of global cancer-related deaths in 2020, according to PubMed. The higher mortality rates are linked to undiagnosed cases, a shortage of diagnostic labs, and insufficient histopathologists in these regions.

CHALLENGE: Lack of Infrastructure and low awareness in middle and low income countries

The burden of cancer and other non-communicable diseases is very high in developing and underdeveloped countries. However, there is a glaring disparity in the access to care and health indicators in these countries as compared to their developed counterparts. This can be attributed to the lack of access to care, the limited availability of resources in terms of infrastructure and manpower, a lack of awareness, and the social stigma associated with cancer. According to the WHO, 44% of the WHO member states report having less than 1 physician per 1000 population. Similarly, according to the 2022 OECD data, China and India, respectively recorded doctor densities of 2.5 and 0.9 doctors per 1,000 people. There is a disproportionate distribution of health workers worldwide. Countries having the lowest relative need to have the highest numbers of health workers, while those with the highest disease burden have a smaller health workforce. The African region has more than 24% of the total global burden of disease but has access to only 3% of health workers and less than 1% of the world’s financial resources.

Tissue Diagnostics Market Ecosystem/Market Map

Tissue  Diagnostics Market Ecosystem

In 2022, Consumables accounted for the largest share in the tissue diagnostics industry, by product.

Based on product, the tissue diagnostics market is segmented into consumables and instruments. Consumables accounted for the largest share of the market in 2022 by product segment. The rise in government and private funding in life sciences and cancer research and growing R&D expenditure by leading pharma companies, are factors expected to drive the growth of this products segment.

In 2022, Immunohistochemistry accounted for the largest share in the tissue diagnostics industry, by technology.

Based on technology, the tissue diagnostics market is segmented into four technology segments, namely, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology & Workflow, and Special Staining. Immunohistochemistry (IHC), accounted for the largest share of the market in 2022 by technology. In IHC technique the antibodies are used to test certain antigens in tissue by combining immunological, anatomical, and biochemical techniques. The detection of antigens is achieved by using antibodies that bind to antigens with high specificity. This technology is widely used in the diagnosis of abnormal cells.

In 2022, Breast Cancer segment accounted for the largest share in the tissue diagnostics industry, by disease type.

Based on disease type, the tissue diagnostics market is segmented into six disease segments, namely, breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, and other disease types. In 2022, breast cancer accounted for the largest share of the market, by disease type. A number of factors led to the formation of breast cancer such as age, change in lifestyle and the use of hormone replacement therapy. Moreover, with a rise in breast cancer screening activities, the segment is expected to witness considerable growth during the forecast period.

In 2022, hospitals accounted for the largest share in the tissue diagnostics industry, by end user.”

Based on end user, the tissue diagnostics market is segmented into Hospitals, Pharmaceutical Companies, Research Laboratories, Contract Research Organizations, and Other End Users. Hospitals accounted for the largest share of the market by end user. The share of the end user segment is owing to the rise in prevalence of cancer and infectious diseases, which require Multi-specialty hospitals, cancer specialty hospitals, or cancer treatment centers. Hospitals generally have in-house laboratories that perform various types of diagnostics & monitoring tests that enable faster and reliable results.

In 2022, North America accounted for the largest share of the tissue diagnostics industry.

Based on Region, The global tissue diagnostics market is segmented into four regions: North America, Europe, Asia Pacific, and Rest of the world. North America accounted for the largest share of the market in 2022. The increasing healthcare expenditure, and high-quality infrastructure for hospitals and clinical laboratories in the region are the major factors driving the growth of market in North America.

Tissue  Diagnostics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The major players in tissue diagnostics market are F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), , PHC Holdings Corporation (Japan), Agilent Technologies Inc. (US), Thermo Fisher Scientific, Inc. (US), These players’ market leadership is due to their broad product portfolios and vast global footprint. These dominant market players have advantages, including strong research and development budgets, better marketing and distribution networks, and established brand recognition.

Scope of the Tissue Diagnostics Industry

Report Metric

Details

Market Revenue in 2023

$5.6 billion

Projected Revenue by 2028

$8.4 billion

Revenue Rate

Poised to Grow at a CAGR of 8.4%

Market Driver

Growing demand for digital pathology

Market Opportunity

Significant opportunities in BRICS Countries

This report categorizes the tissue diagnostics market to forecast revenue and analyze trends in each of the following submarkets:

By Product

  • Consumables
    • Antibodies
    • Kits
    • Reagents
    • Probes
  • Instruments
    • Slide-staining Systems
    • Scanners
    • Tissue-processing Systems
    • Other Instruments (automated cover slippers, microtomes, embedding systems, paraffin dispensers, and slide labelers)

By Technology

  • Immunohistochemistry
  • In Situ Hybridization
  • Digital Pathology & Workflow Management
  • Special Staining

By Disease Type

  • Breast Cancer
  • Gastric Cancer
  • Lymphoma
  • Prostate Cancer
  • Non-small Cell Lung Cancer
  • Other Disease Types (neurological disease, cardiovascular disease, immunological diseases, infectious diseases, cancers of the bone, colon, thyroid, cervix, and skin; gallbladder carcinoma; HBV; Epstein-Barr virus; hepatitis; muscular dystrophy; renal cell carcinoma; and pleomorphic sarcomas.)

By End User

  • Hospitals
  • Research Laboratories
  • Pharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Other End Users (reference laboratories and academic research laboratories)

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Rest of The World (RoW)
    • Latin America
    • Middle East & Africa

Recent Developments of Tissue Diagnostics Industry

  • In April 2023, Leica Biosystems received FDA clearance for BOND MMR Antibody Panel, for detection of colorectal cancer.
  • In April 2023, Leica Biosystems launched its BOND-PRIME an advanced staining solution for increasing diagnostic productivity in the lab
  • In February 2023, F. Hoffman-La Roche Ltd launched its IDH1 R132H (MRQ-67) Rabbit Monoclonal Antibody and the ATRX Rabbit Polyclonal Antibody for use in the BenchMark series of instruments for the detection of brain cancer.
  • In October 2022, F. Hoffman-La Roche Ltd received FDA approval for its PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody use as a companion diagnostic test to identify metastatic breast cancer patients with low HER2 expression.
  • In August 2022, F. Hoffman-La Roche Ltd (Switzerland) received FDA approval its for label expansion for the VENTANA MMR RxDx Panel.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 31)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
    1.3 INCLUSIONS AND EXCLUSIONS 
    1.4 MARKET SCOPE 
           1.4.1 MARKETS COVERED
                    FIGURE 1 MARKET SEGMENTATION
           1.4.2 REGIONS COVERED
           1.4.3 YEARS CONSIDERED
           1.4.4 CURRENCY CONSIDERED
    1.5 STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 36)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                    2.1.2.3 Key industry insights
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,  AND REGION
    2.2 MARKET SIZE ESTIMATION 
           2.2.1 BOTTOM-UP APPROACH
                    FIGURE 5 REVENUE SHARE ANALYSIS
                    FIGURE 6 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
                    FIGURE 7 TISSUE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS 
    2.5 STUDY ASSUMPTIONS 
           2.5.1 MARKET ASSUMPTIONS
           2.5.2 GROWTH RATE ASSUMPTIONS
    2.6 RESEARCH LIMITATIONS 
           2.6.1 METHODOLOGY-RELATED LIMITATIONS
           2.6.2 SCOPE-RELATED LIMITATIONS
    2.7 RISK ASSESSMENT 
          TABLE 1 RISK ASSESSMENT ANALYSIS
    2.8 RECESSION IMPACT ANALYSIS 
 
3 EXECUTIVE SUMMARY (Page No. - 49)
    FIGURE 9 TISSUE DIAGNOSTICS MARKET SHARE, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
    FIGURE 10 TISSUE DIAGNOSTICS INDUSTRY, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
    FIGURE 11 MARKET, BY DISEASE TYPE, 2023 VS. 2028  (USD BILLION)
    FIGURE 12 MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
    FIGURE 13 GEOGRAPHICAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 53)
    4.1 TISSUE DIAGNOSTICS MARKET OVERVIEW 
          FIGURE 14 RISING INCIDENCE OF CANCER AND INFECTIOUS DISEASES TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
    4.2 NORTH AMERICA: TISSUE DIAGNOSTICS INDUSTRY, BY PRODUCT & COUNTRY (2022) 
          FIGURE 15 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.3 MARKET: GEOGRAPHICAL SNAPSHOT 
          FIGURE 16 CHINA & INDIA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
    4.4 MARKET: REGIONAL MIX 
          FIGURE 17 ASIA PACIFIC REGION IS PROJECTED TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
    4.5 MARKET: DEVELOPED COUNTRIES VS. EMERGING ECONOMIES 
          FIGURE 18 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 56)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 19 TISSUE DIAGNOSTICS MARKET SHARE: DRIVERS, RESTRAINTS, OPPORTUNITIES,  AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising incidence of cancer and infectious diseases
                                TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
                                TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS,  2018 VS. 2020 VS. 2040
                    5.2.1.2 Growing demand for digital pathology
                    5.2.1.3 Increasing healthcare expenditure
                                FIGURE 20 CURRENT HEALTH EXPENDITURE PER CAPITA
                                FIGURE 21 CURRENT HEALTH EXPENDITURE (% OF GDP)
                    5.2.1.4 Growing availability of reimbursements
                    5.2.1.5 Rising establishment of private diagnostics centers
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of tissue diagnostic systems
                    5.2.2.2 Stringent regulatory requirements
           5.2.3 OPPORTUNITIES
                    5.2.3.1 High growth potential of emerging economies
                                FIGURE 22 GROWTH IN CURRENT HEALTHCARE EXPENDITURE IN BRICS COUNTRIES,  2012–2020
                    5.2.3.2 Growing preference for personalized medicines
                                FIGURE 23 PERSONALIZED MEDICINES APPROVED BY FDA (%), 2015–2022
                    5.2.3.3 Increasing number of clinical trials for cancer therapeutics
           5.2.4 CHALLENGES
                    5.2.4.1 Shortage of skilled professionals
                    5.2.4.2 Availability of refurbished products
                    5.2.4.3 Inadequate standardization for TDx
           5.2.5 INDUSTRY TRENDS
                    5.2.5.1 Increasing number of reagent rental agreements
                    5.2.5.2 Growing usage of AI in histopathology
    5.3 VALUE CHAIN ANALYSIS 
          FIGURE 24 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
    5.4 SUPPLY CHAIN ANALYSIS 
          FIGURE 25 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
    5.5 TECHNOLOGY ANALYSIS 
    5.6 PORTER’S FIVE FORCES ANALYSIS 
           5.6.1 THREAT OF NEW ENTRANTS
           5.6.2 BARGAINING POWER OF BUYERS
           5.6.3 BARGAINING POWER OF SUPPLIERS
           5.6.4 THREAT OF SUBSTITUTES
           5.6.5 INTENSITY OF COMPETITIVE RIVALRY
    5.7 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USERS
                    TABLE 4 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%)
           5.7.2 BUYING CRITERIA
                    FIGURE 27 KEY BUYING CRITERIA FOR TOP THREE END USERS
                    TABLE 5 KEY BUYING CRITERIA FOR END USERS
    5.8 REGULATORY LANDSCAPE 
          TABLE 6 INDICATIVE LIST OF REGULATORY AUTHORITIES IN TISSUE DIAGNOSTICS INDUSTRY
    5.9 PATENT ANALYSIS 
    5.10 KEY CONFERENCES AND EVENTS 
           TABLE 7 LIST OF CONFERENCES & EVENTS (2023−2024)
    5.11 PRICING ANALYSIS 
           TABLE 8 PRICE RANGE FOR TISSUE DIAGNOSTICS
    5.12 TRADE ANALYSIS 
           TABLE 9 IMPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS  AND APPARATUS FOR PHYSICAL/CHEMICAL ANALYSIS, BY COUNTRY,  2018–2022 (USD MILLION)
           TABLE 10 EXPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS  AND APPARATUS FOR PHYSICAL/CHEMICAL ANALYSIS, BY COUNTRY,  2018–2022 (USD MILLION)
    5.13 ECOSYSTEM MARKET/MAP 
           TABLE 11 MARKET: ROLE IN ECOSYSTEM
           FIGURE 28 KEY PLAYERS OPERATING IN MARKET
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
 
6 TISSUE DIAGNOSTICS MARKET FORECAST, BY PRODUCT (Page No. - 84)
    6.1 INTRODUCTION 
          TABLE 12 TISSUE DIAGNOSTICS INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 CONSUMABLES 
          TABLE 13 MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
          TABLE 14 MARKET FOR CONSUMABLES, BY REGION,  2021–2028 (USD MILLION)
           6.2.1 ANTIBODIES
                    6.2.1.1 Rising prevalence of infectious diseases to drive market
                                TABLE 15 MARKET FOR ANTIBODIES, BY REGION,  2021–2028 (USD MILLION)
           6.2.2 KITS
                    6.2.2.1 Optimized sensitivity and versatility to boost demand
                                TABLE 16 MARKET FOR KITS, BY REGION, 2021–2028 (USD MILLION)
           6.2.3 REAGENTS
                    6.2.3.1 Rising uptake in IHC and FISH procedures to support market growth
                                TABLE 17 MARKET FOR REAGENTS, BY REGION, 2021–2028 (USD MILLION)
           6.2.4 PROBES
                    6.2.4.1 Utilization in fluorescence microscopy applications to boost demand
                                TABLE 18 MARKET FOR PROBES, BY REGION, 2021–2028 (USD MILLION)
    6.3 INSTRUMENTS 
          TABLE 19 MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 20 MARKET FOR INSTRUMENTS, BY REGION,  2021–2028 (USD MILLION)
           6.3.1 SLIDE-STAINING SYSTEMS
                    6.3.1.1 Development of high-throughput staining systems to  drive market
                                TABLE 21 KEY MANUFACTURERS OF AUTOMATED SLIDE STAINERS
                                TABLE 22 MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION,  2021–2028 (USD MILLION)
           6.3.2 SCANNERS
                    6.3.2.1 Rising use of multiplexed IHC scanners to drive market
                                TABLE 23 MARKET FOR SCANNERS, BY REGION, 2021–2028 (USD MILLION)
           6.3.3 TISSUE-PROCESSING SYSTEMS
                    6.3.3.1 Rising need for automation to support market growth
                                TABLE 24 MARKET FOR TISSUE-PROCESSING SYSTEMS, BY REGION,  2021–2028 (USD MILLION)
           6.3.4 OTHER INSTRUMENTS
                    TABLE 25 MARKET FOR OTHER INSTRUMENTS, BY REGION,  2021–2028 (USD MILLION)
 
7 TISSUE DIAGNOSTICS MARKET FORECAST, BY TECHNOLOGY (Page No. - 96)
    7.1 INTRODUCTION 
          TABLE 26 TISSUE DIAGNOSTICS INDUSTRY, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    7.2 IMMUNOHISTOCHEMISTRY 
           7.2.1 RISING UPTAKE OF IHC KITS FOR DIAGNOSTIC APPLICATIONS TO FUEL MARKET
                    TABLE 27 MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION,  2021–2028 (USD MILLION)
    7.3 IN SITU HYBRIDIZATION 
           7.3.1 ABILITY TO DETECT SPECIFIC RNA AND DNA SEQUENCES TO BOOST DEMAND
                    TABLE 28 MARKET FOR IN SITU HYBRIDIZATION, BY REGION,  2021–2028 (USD MILLION)
    7.4 DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT 
           7.4.1 RISING NEED FOR ANALYSIS AND SEAMLESS MANAGEMENT TO SUPPORT MARKET GROWTH
                    TABLE 29 MARKET FOR DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT, BY REGION, 2021–2028 (USD MILLION)
    7.5 SPECIAL STAINING 
           7.5.1 UTILIZATION IN CANCER DIAGNOSTICS TO BOOST DEMAND
                    TABLE 30 MARKET FOR SPECIAL STAINING, BY REGION,  2021–2028 (USD MILLION)
 
8 TISSUE DIAGNOSTICS MARKET FORECAST, BY DISEASE TYPE (Page No. - 102)
    8.1 INTRODUCTION 
          TABLE 31 GLOBAL CANCER INCIDENCE, 2020 VS. 2040
          TABLE 32 TISSUE DIAGNOSTICS INDUSTRY, BY DISEASE TYPE, 2021–2028 (USD MILLION)
    8.2 BREAST CANCER 
           8.2.1 RISING UPTAKE OF HER2 TESTS FOR CANCER DIAGNOSIS TO DRIVE MARKET
                    TABLE 33 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
                    FIGURE 29 ARTICLES PUBLISHED ON BREAST CANCER TISSUE DIAGNOSTICS, 2011–2021
                    TABLE 34 MARKET FOR BREAST CANCER, BY REGION,  2021–2028 (USD MILLION)
    8.3 GASTRIC CANCER 
           8.3.1 RISING INCIDENCE OF GASTROINTESTINAL CANCER TO BOOST DEMAND
                    TABLE 35 COLON CANCER INCIDENCE, BY REGION, 2020 VS. 2040
                    TABLE 36 MARKET FOR GASTRIC CANCER, BY REGION,  2021–2028 (USD MILLION)
    8.4 LYMPHOMA 
           8.4.1 RISING INCIDENCE OF NON-HODGKIN’S LYMPHOMA IN ADULTS TO SUPPORT MARKET GROWTH
                    TABLE 37 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040
                    TABLE 38 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2020 VS. 2040
                    TABLE 39 MARKET FOR LYMPHOMA, BY REGION, 2021–2028 (USD MILLION)
    8.5 PROSTATE CANCER 
           8.5.1 RISING UPTAKE OF ISH TESTS FOR DIAGNOSIS TO FUEL MARKET
                    TABLE 40 PROSTATE CANCER INCIDENCE, BY REGION, 2020 VS. 2040
                    TABLE 41 MARKET FOR PROSTATE CANCER, BY REGION,  2021–2028 (USD MILLION)
    8.6 NON-SMALL CELL LUNG CANCER 
           8.6.1 GROWING FOCUS ON DEVELOPING COMPANION DIAGNOSTIC TESTS TO DRIVE MARKET
                    TABLE 42 MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION,  2021–2028 (USD MILLION)
    8.7 OTHER DISEASE TYPES 
          TABLE 43 MARKET FOR OTHER DISEASE TYPES, BY REGION,  2021–2028 (USD MILLION)
 
9 TISSUE DIAGNOSTICS MARKET FORECAST, BY END USER (Page No. - 112)
    9.1 INTRODUCTION 
          TABLE 44 TISSUE DIAGNOSTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    9.2 HOSPITALS 
           9.2.1 ABILITY TO OFFER ADVANCED EQUIPMENT & INFRASTRUCTURE TO DRIVE MARKET
                    TABLE 45 MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
    9.3 RESEARCH LABORATORIES 
           9.3.1 RISING DEMAND OF SPECIALTY TESTS TO DRIVE MARKET
                    TABLE 46 MARKET FOR RESEARCH LABORATORIES, BY REGION,  2021–2028 (USD MILLION)
    9.4 PHARMACEUTICAL COMPANIES 
           9.4.1 INCREASING R&D ACTIVITIES FOR DISEASE DIAGNOSTICS TO DRIVE MARKET
                    TABLE 47 MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION,  2021–2028 (USD MILLION)
    9.5 CONTRACT RESEARCH ORGANIZATIONS 
           9.5.1 OUTSOURCING OF R&D ACTIVITIES TO SUPPORT MARKET GROWTH
                    TABLE 48 CONTRACT RESEARCH ORGANIZATIONS FOR ONCOLOGY DIAGNOSTICS
                    TABLE 49 MARKET FOR CONTRACT RESEARCH ORGANIZATIONS,  BY REGION, 2021–2028 (USD MILLION)
    9.6 OTHER END USERS 
          TABLE 50 TISSUE DIAGNOSTICS MARKET RESEARCH FOR OTHER END USERS, BY REGION,  2021–2028 (USD MILLION)
 
10 TISSUE DIAGNOSTICS MARKET FORECAST, BY REGION (Page No. - 118)
     10.1 INTRODUCTION 
             TABLE 51 TISSUE DIAGNOSTICS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 30 MARKET: NORTH AMERICA SNAPSHOT
             TABLE 52 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET SHARE, BY COUNTRY,  2021–2028 (USD MILLION)
             TABLE 53 NORTH AMERICA: MARKET, BY PRODUCT,  2021–2028 (USD MILLION)
             TABLE 54 NORTH AMERICA: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 55 NORTH AMERICA: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 56 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET REPORT, BY DISEASE TYPE,  2021–2028 (USD MILLION)
             TABLE 57 NORTH AMERICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
             TABLE 58 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET RESEARCH, BY END USER,  2021–2028 (USD MILLION)
             10.2.1 US
                        10.2.1.1 High healthcare expenditure to drive market
                                      TABLE 59 US CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 60 US: KEY MACROINDICATORS
                                      TABLE 61 LIST OF US FDA-APPROVED PRODUCTS FOR TISSUE DIAGNOSTICS
                                      TABLE 62 US: TISSUE DIAGNOSTICS MARKET SHARE, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 63 US: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 64 US: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 65 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 66 US: TISSUE DIAGNOSTICS MARKET RESEARCH, BY END USER, 2021–2028 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 High prevalence of cancer to support market growth
                                      TABLE 67 CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040
                                      TABLE 68 CANADA: TISSUE DIAGNOSTICS MARKET SHARE, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 69 CANADA: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 70 CANADA: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 71 CANADA: TISSUE DIAGNOSTICS MARKET REPORT, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 72 CANADA: TISSUE DIAGNOSTICS MARKET RESEARCH, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 NORTH AMERICA: RECESSION IMPACT
     10.3 EUROPE 
             TABLE 73 EUROPE: TISSUE DIAGNOSTICS MARKET TRENDS, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 74 EUROPE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 75 EUROPE: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 76 EUROPE: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 77 EUROPE: MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION)
             TABLE 78 EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 79 EUROPE: TISSUE DIAGNOSTICS MARKET RESEARCH, BY END USER, 2021–2028 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Availability of reimbursements for colorectal cancer screening procedures to support market growth
                                      TABLE 80 GERMANY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
                                      TABLE 81 GERMANY: TISSUE DIAGNOSTICS MARKET TRENDS, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 82 GERMANY: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 83 GERMANY: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 84 GERMANY: TISSUE DIAGNOSTICS MARKET REPORT, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 85 GERMANY: TISSUE DIAGNOSTICS MARKET ANALYSIS, BY END USER, 2021–2028 (USD MILLION
             10.3.2 UK
                        10.3.2.1 Rising investments in cancer research to propel market
                                      TABLE 86 UK: TISSUE DIAGNOSTICS MARKET TRENDS, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 87 UK: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 88 UK: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 89 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 90 UK: TISSUE DIAGNOSTICS MARKET ANALYSIS, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Growing focus on early disease diagnosis to boost demand
                                      TABLE 91 FRANCE: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
                                      TABLE 92 FRANCE: TISSUE DIAGNOSTICS MARKET TRENDS, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 93 FRANCE: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 94 FRANCE: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 95 FRANCE: TISSUE DIAGNOSTICS MARKET REPORT, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 96 FRANCE: TISSUE DIAGNOSTICS MARKET ANALYSIS, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 High incidence of cancer and geriatric population to support market growth
                                      TABLE 97 ITALY: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
                                      TABLE 98 ITALY: TISSUE DIAGNOSTICS MARKET TRENDS, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 99 ITALY: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 100 ITALY: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 101 ITALY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 102 ITALY: TISSUE DIAGNOSTICS MARKET ANALYSIS, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 High incidence of chronic diseases to drive market
                                      TABLE 103 SPAIN: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
                                      TABLE 104 SPAIN: TISSUE DIAGNOSTICS MARKET OVERVIEW, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 105 SPAIN: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 106 SPAIN: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 107 SPAIN: TISSUE DIAGNOSTICS MARKET REPORT, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 108 SPAIN: TISSUE DIAGNOSTICS MARKET ANALYSIS, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 REST OF EUROPE
                        TABLE 109 REST OF EUROPE: CANCER INCIDENCE, 2020 VS. 2025
                        TABLE 110 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET OVERVIEW, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 111 REST OF EUROPE: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 112 REST OF EUROPE: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 113 REST OF EUROPE: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 114 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET DEMAND, BY END USER,  2021–2028 (USD MILLION)
             10.3.7 EUROPE: RECESSION IMPACT
     10.4 ASIA PACIFIC 
             FIGURE 31 MARKET: ASIA PACIFIC SNAPSHOT
             TABLE 115 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET OVERVIEW, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 116 ASIA PACIFIC: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 117 ASIA PACIFIC: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 118 ASIA PACIFIC: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 119 ASIA PACIFIC: MARKET, BY DISEASE, 2021–2028 (USD MILLION)
             TABLE 120 ASIA PACIFIC: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
             TABLE 121 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET DEMAND, BY END USER, 2021–2028 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 Rising incidence of chronic & infectious diseases to propel market
                                      TABLE 122 CANCER INCIDENCE, BY CANCER TYPE (CHINA), 2020 VS. 2025
                                      TABLE 123 CHINA: TISSUE DIAGNOSTICS MARKET OVERVIEW, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 124 CHINA: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 125 CHINA: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 126 CHINA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 127 CHINA: TISSUE DIAGNOSTICS MARKET DEMAND, BY END USER, 2021–2028 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Development of advanced diagnostic products to fuel market
                                      TABLE 128 CANCER INCIDENCE, BY CANCER TYPE (JAPAN), 2020 VS. 2040
                                      TABLE 129 JAPAN: TISSUE DIAGNOSTICS MARKET GROWTH, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 130 JAPAN: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 131 JAPAN: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 132 JAPAN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 133 JAPAN: TISSUE DIAGNOSTICS MARKET DEMAND, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Rising establishment of diagnostic centers to drive market
                                      TABLE 134 INDIA: CANCER INCIDENCE, BY TYPE, 2020 VS. 2025
                                      TABLE 135 INDIA: TISSUE DIAGNOSTICS MARKET GROWTH, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 136 INDIA: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 137 INDIA: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 138 INDIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                      TABLE 139 INDIA: TISSUE DIAGNOSTICS MARKET DEMAND, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC
                        TABLE 140 REST OF ASIA PACIFIC: CANCER INCIDENCE, 2020 VS. 2040
                        TABLE 141 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET GROWTH, BY PRODUCT,  2021–2028 (USD MILLION)
                        TABLE 142 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET REPORT FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 143 REST OF ASIA PACIFIC: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
                        TABLE 144 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                        TABLE 145 REST OF ASIA PACIFIC: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.4.5 ASIA PACIFIC: RECESSION IMPACT
     10.5 REST OF THE WORLD 
             TABLE 146 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET GROWTH, BY REGION,  2021–2028 (USD MILLION)
             TABLE 147 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET REPORT, BY PRODUCT,  2021–2028 (USD MILLION)
             TABLE 148 REST OF THE WORLD: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 149 REST OF THE WORLD: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
             TABLE 150 REST OF THE WORLD: MARKET, BY DISEASE TYPE,  2021–2028 (USD MILLION)
             TABLE 151 REST OF THE WORLD: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
             TABLE 152 REST OF THE WORLD: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.5.1 LATIN AMERICA
                        10.5.1.1 Rising number of cancer screening programs to drive market
                                      TABLE 153 LATIN AMERICA: CANCER INCIDENCE, 2020 VS. 2025
                                      TABLE 154 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET GROWTH BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 155 LATIN AMERICA: MARKET FOR CONSUMABLES, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 156 LATIN AMERICA: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 157 LATIN AMERICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 158 LATIN AMERICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.5.2 MIDDLE EAST & AFRICA
                        10.5.2.1 Improvements in healthcare infrastructure to support market growth
                                      TABLE 159 CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2025
                                      TABLE 160 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET REPORT, BY PRODUCT,  2021–2028 (USD MILLION)
                                      TABLE 161 MIDDLE EAST & AFRICA: MARKET FOR CONSUMABLES,  BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 162 MIDDLE EAST & AFRICA: MARKET FOR INSTRUMENTS, BY TYPE,  2021–2028 (USD MILLION)
                                      TABLE 163 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY,  2021–2028 (USD MILLION)
                                      TABLE 164 MIDDLE EAST & AFRICA: MARKET, BY END USER,  2021–2028 (USD MILLION)
             10.5.3 REST OF THE WORLD: RECESSION IMPACT
 
11 COMPETITIVE LANDSCAPE (Page No. - 174)
     11.1 OVERVIEW 
     11.2 KEY PLAYER STRATEGIES 
             11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY MARKET PLAYERS
                        TABLE 165 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET
     11.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN TISSUE DIAGNOSTICS INDUSTRY
     11.4 MARKET SHARE ANALYSIS 
             TABLE 166 TISSUE DIAGNOSTICS INDUSTRY: INTENSITY OF COMPETITIVE RIVALRY
             FIGURE 33 TISSUE DIAGNOSTICS INDUSTRY SHARE, BY KEY PLAYER (2022)
     11.5 COMPANY EVALUATION MATRIX 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 34 TISSUE DIAGNOSTICS INDUSTRY: COMPANY EVALUATION MATRIX
             11.5.5 COMPETITIVE BENCHMARKING OF KEY PLAYERS
                        TABLE 167 COMPANY FOOTPRINT
             11.5.6 PRODUCT FOOTPRINT
             11.5.7 REGIONAL FOOTPRINT
     11.6 START-UP/SME EVALUATION MATRIX 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 RESPONSIVE COMPANIES
             11.6.3 DYNAMIC COMPANIES
             11.6.4 STARTING BLOCKS
                        FIGURE 35 TISSUE DIAGNOSTICS INDUSTRY: COMPANY EVALUATION MATRIX FOR  START-UPS/SMES
     11.7 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 
             TABLE 168 TISSUE DIAGNOSTICS MARKET REPORT: KEY STARTUPS/SMES
     11.8 COMPETITIVE SCENARIOS AND TRENDS 
             11.8.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 169 TISSUE DIAGNOSTICS INDUSTRY: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020−OCTOBER 2023)
             11.8.2 DEALS
                        TABLE 170 TISSUE DIAGNOSTICS MARKET REPORT: DEALS (JANUARY 2020−OCTOBER 2023)
             11.8.3 OTHER DEVELOPMENTS
                        TABLE 171 TISSUE DIAGNOSTIC MARKET: OTHER DEVELOPMENTS (JANUARY 2020−OCTOBER 2023)
 
12 COMPANY PROFILES (Page No. - 190)
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
     12.1 KEY PLAYERS 
             12.1.1 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 172 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
             12.1.2 DANAHER CORPORATION
                        TABLE 173 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.3 PHC HOLDINGS CORPORATION
                        TABLE 174 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 38 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
             12.1.4 THERMO FISHER SCIENTIFIC INC.
                        TABLE 175 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 39 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             12.1.5 ABBOTT
                        TABLE 176 ABBOTT: BUSINESS OVERVIEW
                        FIGURE 40 ABBOTT: COMPANY SNAPSHOT (2022)
             12.1.6 AGILENT TECHNOLOGIES, INC.
                        TABLE 177 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 41 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2022)
             12.1.7 MERCK KGAA
                        TABLE 178 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2022)
             12.1.8 SAKURA FINETEK JAPAN CO., LTD.
                        TABLE 179 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW
             12.1.9 ABCAM PLC
                        TABLE 180 ABCAM PLC.: BUSINESS OVERVIEW
                        FIGURE 43 ABCAM PLC. COMPANY SNAPSHOT (2022)
             12.1.10 BECTON, DICKINSON AND COMPANY (BD)
                        TABLE 181 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 44 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
             12.1.11 BIO SB
                        TABLE 182 BIO SB: BUSINESS OVERVIEW
             12.1.12 BIOGENEX
                        TABLE 183 BIOGENEX: BUSINESS OVERVIEW
             12.1.13 CELL SIGNALING TECHNOLOGY, INC.
                        TABLE 184 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
             12.1.14 HISTO-LINE LABORATORIES
                        TABLE 185 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW
             12.1.15 SLEE MEDICAL GMBH
                        TABLE 186 SLEE MEDICAL GMBH: BUSINESS OVERVIEW
             12.1.16 CELLPATH LTD.
                        TABLE 187 CELLPATH LTD.: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS 
             12.2.1 AMOS SCIENTIFIC PTY LTD.
             12.2.2 JINHUA YIDI MEDICAL APPLIANCE CO., LTD.
             12.2.3 MEDITE MEDICAL GMBH
             12.2.4 DIAPATH S.P.A.
             12.2.5 KFBIO KONFOONG BIOINFORMATION TECH CO., LTD
             12.2.6 DIAGNOSTIC BIOSYSTEMS INC.
             12.2.7 3DHISTECH LTD.
             12.2.8 RWD LIFE SCIENCE CO., LTD.
             12.2.9 DAKEWE
             12.2.10 SYSMEX CORPORATION
             12.2.11 ENZO LIFE SCIENCES, INC.
             12.2.12 BIOCARE MEDICAL, LLC.
             12.2.13 MILESTONE MEDICAL
             12.2.14 BIO-OPTICA MILANO SPA
 
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 253)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

The objective of the study is to analyze the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies’ developments such as product launches and approvals, expansions, and partnerships of the leading players, the competitive landscape of the tissue diagnostics market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.

The four steps involved in estimating the market size are

Collecting Secondary Data

The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the tissue diagnostics market. A database of the key industry leaders was also prepared using secondary research.

Collecting Primary Data

The primary research data was conducted after acquiring knowledge about the tissue diagnostics market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as doctors, nurses, and hospital purchase managers) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, and Rest of the World. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.

A breakdown of the primary respondents is provided below:

Breakdown of Primary Participants:

Tissue  Diagnostics Market Size, and Share

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Tiers are defined based on a company’s total revenue. As of 2022: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME

DESIGNATION

F. Hoffmann-La Roche Ltd (Switzerland)

Product Manager

Danaher Corporation (US)

VP Sales

Thermo Fisher Scientific Inc. (US)

Regional Sales Head

Abbott Laboratories (US)

Sales Director

Market Size Estimation

All major manufacturers offering various tissue diagnostics product were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The value of tissue diagnostics market was also split into various segments and subsegments at the region and country level based on:

  • Product mapping of various manufacturers for each type of tissue diagnostics products at the regional and country level
  • Relative adoption pattern of each product type among key disease segments at the regional and/or country-level
  • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country level.
  • Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level

Global Tissue Diagnostics Market Size: Botton Up Approach

Tissue  Diagnostics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global tissue diagnostics Market Size: Top Down Approach

Tissue  Diagnostics Market Size, and Share

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the tissue diagnostics industry.

Market Definition

Tissue-based diagnostics tests are performed for screening, diagnosing, and monitoring the response of cancer patients to therapy. Tissue diagnosis refers to the examination of intact tissues obtained during a medical procedure such as biopsies and surgeries. Tissue-based diagnostic tests are used in the treatment of breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, and other diseases (bone cancer, cervical cancer, colon cancer, cervix cancer, gallbladder carcinoma, skin cancer, HBV, Epstein-Barr virus, hepatitis, and muscular dystrophies). These diagnostics tests are carried out to identify a medical condition in its early stage so as to establish the correct course of treatment. Tissue diagnostic tests are also carried out to determine the course of recovery and response to the treatment.

Key Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department
  • R&D Department

Report Objectives

  • To provide detailed information about the factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To define, describe, segment, and forecast the tissue diagnostics market by product, technology, disease type, and end user, and region
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall tissue diagnostics market
  • To forecast the size of the tissue diagnostics market in four main regions along with their respective key countries, namely, North America, Europe, Asia Pacific, and Rest of the World.
  • To profile key players in the tissue diagnostics market and comprehensively analyze their core competencies and market shares
  • To track and analyze competitive developments, such as product launches and approvals; expansions; and partnerships; of the leading players in the tissue diagnostics market
  • To benchmark players within the tissue diagnostics market using the Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographic Analysis

  • Further breakdown of the tissue diagnostics market into specific countries/regions in the Rest of Europe, Rest of Asia Pacific, and Rest of the World.

Company Information

  • Detailed analysis and profiling of additional market players (up to 3)
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 2349
Published ON
Jan, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Tissue Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback